Mei-Yin Hsu

Title: Innovations of Mei-Yin Hsu in Blood Clotting Research

Introduction

Mei-Yin Hsu is an accomplished inventor based in Hillsboro, NJ (US). She has made significant contributions to the field of blood clotting research, holding a total of 3 patents. Her work focuses on the development of novel therapeutic agents that can regulate blood clotting, which is crucial for treating various blood disorders.

Latest Patents

One of her latest patents involves the discovery of baboon thrombin-activatable fibrinolysis inhibitors, known as TAFI. This invention relates to the isolation and identification of novel baboon nucleic acid molecules and the proteins and polypeptides encoded by these nucleic acids. The TAFI proteins and polypeptides inhibit the breakdown of blood clots, making them potentially useful for treating conditions such as hemophilia and von Willebrand's disease. Additionally, these sequences can be utilized in screening methods to identify compounds that modulate the expression of baboon TAFI nucleic acids and/or the activity of the corresponding proteins and polypeptides. Such compounds may serve as agonists or antagonists in the treatment of various thrombotic diseases.

Career Highlights

Throughout her career, Mei-Yin Hsu has worked with prominent organizations, including Bristol-Myers Squibb Company and The General Hospital Corporation. Her experience in these institutions has allowed her to advance her research and contribute to significant innovations in the medical field.

Collaborations

Mei-Yin has collaborated with notable colleagues, including Gary R. Matsueda and James K. Tamura. These partnerships have further enriched her research endeavors and have led to impactful advancements in blood clotting therapies.

Conclusion

Mei-Yin Hsu's innovative work in the field of blood clotting research exemplifies her dedication to improving therapeutic options for patients with blood disorders. Her patents and collaborations highlight her significant contributions to medical science.